anonymous
Guest
anonymous
Guest
Remember The New Day Study? Back in 2020 their former CMO stated “Alimera expects to incur approximately $13.5 million over the next three to four years associated with the NEW DAY Study and to fund these costs with existing resources, cash flow from operations and the redeployment of other clinical spending.” With the current financial results how can they continue to pay for this and run their commercial operations?
By the time the study reports in 2024, aflibercept the comparator drug in the study will be near to patent expiry so the competitor landscape will change and customers will not be interested.
By the time the study reports in 2024, aflibercept the comparator drug in the study will be near to patent expiry so the competitor landscape will change and customers will not be interested.